Solanezumab
Solanezumab is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
4
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
4 of 8 finished
50.0%
4 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Clinical Trials (9)
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9